Rolfes, Leoni, Pawlitzki, Marc, Pfeuffer, Steffen, Nelke, Christopher, Lux, Anke, Pul, Refik, Kleinschnitz, Christoph ORCID: 0000-0002-1650-8875, Kleinschnitz, Konstanze, Rogall, Rebeca, Pape, Katrin, Bittner, Stefan, Zipp, Frauke ORCID: 0000-0002-1231-1928, Warnke, Clemens, Goereci, Yasemin, Schroeter, Michael, Ingwersen, Jens, Aktas, Orhan, Klotz, Luisa, Ruck, Tobias ORCID: 0000-0001-6332-8650, Wiendl, Heinz and Meuth, Sven G. (2021). Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. Neurol.-Neuroimmunol. Neuroinflammation, 8 (5). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2332-7812

Full text not available from this repository.

Abstract

Objective To evaluate the clinical consequences of extended interval dosing (EID) of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease 2019 (COVID-19) pandemic. Methods In our retrospective, multicenter cohort study, we compared patients with RRMS on EID (defined as >= 4-week delay of dose interval) with a control group on standard interval dosing (SID) at the same period (January to December 2020). Results Three hundred eighteen patients with RRMS were longitudinally evaluated in 5 German centers. One hundred sixteen patients received ocrelizumab on EID (median delay [interquartile range 8.68 [5.09-13.07] weeks). Three months after the last ocrelizumab infusion, 182 (90.1%) patients following SID and 105 (90.5%) EID patients remained relapse free (p = 0.903). Three-month confirmed progression of disability was observed in 18 SID patients (8.9%) and 11 EID patients (9.5%, p = 0.433). MRI progression was documented in 9 SID patients (4.5%) and 8 EID patients (6.9%) at 3-month follow-up (p = 0.232). Multivariate logistic regression showed no association between treatment regimen and no evidence of disease activity status at follow-up (OR: 1.266 [95% CI: 0.695-2.305]; p = 0.441). Clinical stability was accompanied by persistent peripheral CD19(+) B-cell depletion in both groups (SID vs EID: 82.6% vs 83.3%, p = 0.463). Disease activity in our cohort was not associated with CD19(+) B-cell repopulation. Conclusion Our data support EID of ocrelizumab as potential risk mitigation strategy in times of the COVID-19 pandemic. Classification of Evidence This study provides Class IV evidence that for patients with RRMS, an EID of at least 4 weeks does not diminish effectiveness of ocrelizumab.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Rolfes, LeoniUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pawlitzki, MarcUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pfeuffer, SteffenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nelke, ChristopherUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lux, AnkeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pul, RefikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kleinschnitz, ChristophUNSPECIFIEDorcid.org/0000-0002-1650-8875UNSPECIFIED
Kleinschnitz, KonstanzeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rogall, RebecaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pape, KatrinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bittner, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zipp, FraukeUNSPECIFIEDorcid.org/0000-0002-1231-1928UNSPECIFIED
Warnke, ClemensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goereci, YaseminUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schroeter, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ingwersen, JensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aktas, OrhanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Klotz, LuisaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ruck, TobiasUNSPECIFIEDorcid.org/0000-0001-6332-8650UNSPECIFIED
Wiendl, HeinzUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meuth, Sven G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-594285
DOI: 10.1212/NXI.0000000000001035
Journal or Publication Title: Neurol.-Neuroimmunol. Neuroinflammation
Volume: 8
Number: 5
Date: 2021
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Place of Publication: PHILADELPHIA
ISSN: 2332-7812
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
NEUROMYELITIS-OPTICAMultiple languages
Clinical Neurology; NeurosciencesMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/59428

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item